M&A Deal Summary

GE Healthcare Acquires Applied Precision

On April 28, 2011, GE Healthcare acquired test/measurement equipment company Applied Precision from Telegraph Hill Partners

Acquisition Highlights
  • This is GE Healthcare’s 1st transaction in the Test/Measurement Equipment sector.
  • This is GE Healthcare’s 11th transaction in the United States.
  • This is GE Healthcare’s 2nd transaction in Washington.

M&A Deal Summary

Date 2011-04-28
Target Applied Precision
Sector Test/Measurement Equipment
Buyer(s) GE Healthcare
Sellers(s) Telegraph Hill Partners
Deal Type Add-on Acquisition

Target

Applied Precision

Issaquah, Washington, United States
website
Applied Precision, Inc. was a provider of imaging, measurement and analysis systems for the Life Sciences industries and OEM markets. Applied Precision was formed in 1986 and was based in Issaquah, Washington.

Search 191,543 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

GE Healthcare

Westborough, Massachusetts, United States

website


Category Company
Founded 1994
Sector Medical Products
DESCRIPTION

GE Healthcare, a unit of General Electric Company is a provider of medical technologies and services. GE Healthcare has expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, life sciences, drug discovery, and biopharmaceutical manufacturing technologies. GE Healthcare is based in Westborough, Massachusetts.


DEAL STATS #
Overall 13 of 29
Sector (Test/Measurement Equipment) 1 of 1
Type (Add-on Acquisition) 13 of 26
State (Washington) 2 of 2
Country (United States) 11 of 21
Year (2011) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-12-22 Clarient

Aliso Viejo, California, United States

Clarient, Inc. is a provider of comprehensive cancer diagnostic testing to hospitals and physicians in the pharmaceutical industry.

Buy $587M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-03-07 Xcellerex

Marlborough, Massachusetts, United States

Xcellerex is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines.

Buy -

Seller(S) 1

SELLER

Telegraph Hill Partners

San Francisco, California, United States

Investor Investor Investor Investor Investor

website


Category Venture Capital Firm
Founded 2001
Size Middle-Market
Type Sector Focused
DESCRIPTION

Telegraph Hill Partners is a specialist private equity firm focused on investing in later-stage life science, medical device, and healthcare companies. Prospective companies should be at or near profitability and demonstrate success. Other areas of interest within the healthcare sector include life science technologies, chemistry/reagent suppliers, and information management. Telegraph Hill Partners was formed in 2001 and is based in San Francisco, California.


DEAL STATS #
Overall 7 of 28
Sector (Test/Measurement Equipment) 1 of 1
Type (Add-on Acquisition) 7 of 23
State (Washington) 1 of 1
Country (United States) 7 of 27
Year (2011) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-04-13 AltheaDx

San Diego, California, United States

AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenetics, or PGx. AltheaDx's product testing portfolio enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders, and pain. AltheaDx was founded in 1998 and is based in San Diego, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-07-26 NEXUS Biosystems

Poway, California, United States

NEXUS Biosystems, Inc. is a developer and provider of enabling technologies and automation systems for sample storage and management to pharmaceutical, biotech, agrochemical and academic research institutions worldwide.

Sell $79M